Approximately one in five breast cancers are driven by amplification and overexpression of the human epidermal growth factor receptor 2 (HER2) receptor kinase, and HER2-enriched (HER2E) is one of four major transcriptional subtypes of breast cancer. We set out to understand the genomics of HER2 ...
Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2) are associated with the development of many tumors. It is currently a crucial treatment for multiple cancers. Advanced in molecular biology and further exploration of the HER2-mediated pathway have promoted the...
In hypoxic cells, PHD-mediated hydroxylation of HIF-α is restricted by the low availability of molecular oxygen. This results in an accumulation of HIF-α subunits, which are then able to form active dimers with HIF-β and drive the transcription of hypoxia response genes [7,8,9]. HIF-1...
HER2 is a member of the ErbB receptor tyrosine kinase family that is involved in cell proliferation and angiogenesis [149] and plays an important role in the pathogenesis of various cancers [150]. The PanErbB inhibitor Afatinib has been reported an effective drug for the treatment of HER2 posit...
HER2-targeted therapies are developed to counteract the overexpression or amplification of HER2 protein in cancers, particularly BC. Trastuzumab, a monoclonal antibody targeting the HER2 receptor, stands out as the most prevalent HER2-targeted treatment. Additional therapies, such as pertuzumab, ado-trast...
the DNA nanorobot may not be able to achieve a significant effect on the treatment. HER2, as one of the transmembrane epidermal growth factor receptors (EGFRs), is involved in various types of information signaling processes among cancer cells. HER2 can enhance the malignancy of breast cancer. ...
HER2 CAR-NK-92 cells manifested specific antitumor cytotoxicity against ErbB2-expressing breast cancer cells in vitro. Additionally, they significantly reduced metastasis formation of ErbB2-expressing renal cell carcinoma cells [184]. EGFR-CAR-NK cells demonstrated a substantial inhibition of tumor ...
Sub-clonal evolution of MET amplification in KRAS (G12C) NSCLC cells that have become resistant to AMG510 in vitro has been reported previously [112]. Amplified MET increases the active form of RAS. Besides, MET also enhances AKT activation in the absence of RAS [112]. Criztinib is an...
(Ibrance). Study data from the combination cohort demonstrated encouraging clinical activity in heavily pre-treated patients with a median of four lines of therapy across disease settings with locally advanced or metastatic ER positive/human epidermal growth factor 2 (HER2) negative...
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for about 20% of all breast cancer cases and is correlated with a high relapse rate and poor prognosis. ADAMTS18 is proposed as an important functional tumor suppressor gene